Richmond, VANCT06370000Now EnrollingIRB Ready

Acute Myeloid Leukemia Clinical Trial in Richmond, VA

Access cutting-edge acute myeloid leukemia treatment through this clinical trial at a research site in Richmond. Study-provided care at no cost to qualified participants.

Sponsored by Virginia Commonwealth University

Quick Self-Assessment

See if you qualify for this Richmond location

Preparing your pre-screening questions…

Expert Care in Richmond

Access acute myeloid leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute myeloid leukemia treatment provided free

Apply for This Richmond Location

Check if you qualify for this acute myeloid leukemia clinical trial in Richmond, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Richmond

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Richmond site if eligible
  4. 4Begin participation

About This Acute Myeloid Leukemia Study in Richmond

Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains

Sponsor: Virginia Commonwealth University

Who Can Participate

Inclusion Criteria

Patients must have histologically or cytologically confirmed non-Acute Promyelocytic (APL) FLT3 negative AML and have completed induction and consolidation as defined by the treating physician and must be in complete response (CR), Complete response with partial hematologic recovery (CRh), or Complete response with incomplete count recovery (CRi) at time of study enrollment
For patients in CR1, AML disease phenotype must be one that is considered for allo HCT in CR1 (intermediate or high risk by European Leukemia Net (ELN), MRD+ CR, slow clearance of MRD) or any AML phenotype (aside from FLT3+ and APL) in CR2 and beyond
Medically eligible for allogeneic hematopoietic cell transplant (allo HCT) as defined by either: treating physician discretion, transplant physician discretion, or hematopoietic cell transplantation-specific Comorbidity index (HCT-CI) index of 5 or less
Age ≥ 18 years
Enrollment must occur within 4 months of completion of therapy
A patient or staff identified health disparity in 1 of the 5 Centers for Disease Control (CDC) defined social determinants of health (SDOH). This may include financial difficulties, lack of caregiver support, difficulties with medical literacy, rurality, appropriate access to health care, lack of an appropriate allogeneic hematopoietic cell transplant (allo HCT) donor, substance abuse
Patient must have adequate organ function defined as: Creatinine clearance (by Cockroft-Gault formula) greater than or equal to 29 mL/min, total bilirubin and aspartate aminotransferase/ alanine transaminase (AST/ALT) ≤ to institutional 2x upper limit of normal (except Gilbert's syndrome, which may enroll if \< 2x patient's baseline total bilirubin)
Eastern Cooperative Oncology Group (ECOG) 0,1,2,3
Ability to take oral medications
No history of malabsorption syndrome which, in the investigator's opinion, may inhibit absorption of oral medications
Women of childbearing potential must consent to effective contraception during study treatment and at least 6 months following the last dose. Women who are breastfeeding are also excluded
Male patients must consent to effective contraception during study and at least 3 months after last dose
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

A patient who meets any of the following exclusion criteria is ineligible to participate in the study.
FMS-like tyrosine kinase 3 (FLT3 ITD) or tyrosine kinase domain (TKD) mutation
Uncontrolled central nervous system (CNS) involvement
History of hypersensitivity or allergic reaction to azacitidine or its components
Stem cell transplant within previous 3 months prior to initiation of study therapy
Uncontrolled intercurrent illness or infection
History of prior therapy with oral azacitidine
Female patients who are pregnant or intend to donate eggs during the study or for 6 months after receiving their last dose of study drug
Male patients who intend to donate sperm during the course of this study or for 3 months after last dose
Other malignancy for which the patient is currently receiving therapy (except excisable skin cancer)
Medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk or limit the participant's adherence with study requirements

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Richmond?

Yes, this clinical trial (NCT06370000) has an active research site in Richmond, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Myeloid Leukemia Treatment Options in Richmond, VA

If you're searching for acute myeloid leukemia treatment options in Richmond, VA, this clinical trial (NCT06370000) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Richmond research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute myeloid leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Richmond, VA

See all leukemia clinical trials recruiting in Richmond — not just this study.

Browse Leukemia Trials in Richmond →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsHeart Attack TrialsMyocardial Infarction TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Richmond?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Richmond, VA